statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

On Thursday, Spotify, Lockheed Martin and Ionia Pharmaceuticals witnessed upgrades by well-known brokerage firms. Here’s a look at how retail investors are reacting to the news:1. Spotify: Goldman Sachs has reportedly upgraded&nbsp;Spotify&nbsp;to ‘Buy’ from ‘Neutral’ while raising the price target to $425, up from the earlier target of $320. Goldman believes Spotify is the clear global audio platform leader and this could translate into compounded user growth, rising engagement, and pricing power. Spotify recently reported an upbeat set of numbers with earnings per share (EPS) coming in at €1.33, higher than a Street estimate of €1.05. Revenue came in at €3.81 billion during the second quarter, marginally lower than an estimate of €3.82 billion. Premium revenue came in at €3.35 billion, higher than an estimate of €3.34 billion. Despite the upgrade, retail investors are undecided on the stock with the sentiment meter trending in the neutral zone (50/100).<figure class="image"><img style="aspect-ratio:796/235;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_07_24_at_11_48_15_AM_3ec5ba958d.png" alt="Retail sentiment trends in the neutral zone for Spotify despite an upgrade" width="796" height="235"><figcaption>Retail sentiment trends in the neutral zone for Spotify despite an upgrade</figcaption></figure>2. Lockheed Martin: TD Cowen reportedly upgraded&nbsp;the stock&nbsp;to ‘Buy’ from ‘Hold’ while increasing the price target of $560 from an earlier target of $480. TD Cowen believes Lockheed’s strong Q2 and F-35 delivery restart provides better visibility of 5% sales gains, along with improvement in margin and rising cash flow through 2026. On Tuesday, Lockheed reported net sales of&nbsp;$18.1 billion, compared to&nbsp;$16.7 billion&nbsp;in the second quarter of 2023. Net earnings came in at&nbsp;$1.6 billion, or&nbsp;$6.85&nbsp;per share, compared to&nbsp;$1.7 billion, or&nbsp;$6.63&nbsp;per share, in the second quarter of 2023.&nbsp;Shares of the firm gained nearly 6% in the last five days. Retail investors are optimistic about the stock, with the sentiment meter trending in the bullish territory (66/100) supported by extremely high message volume.3. Ionis Pharmaceuticals: Leerink Partners has reportedly upgraded&nbsp;Ionis Pharmaceuticals&nbsp;to ‘Outperform’ from ‘Market Perform’ while raising the price target to $62 from the earlier target of $53. The upgrade comes after Ionis Pharmaceuticals announced positive results for its Angelman syndrome drug. The firm said it is looking forward to collaborating with investigators, regulators and members of the Angelman syndrome community to initiate Phase 3 development for its drug in the first half of 2025. Despite the upgrade and the positive results, retail investors appear to be undecided on the stock with the sentiment meter trending in the neutral territory (52/100) on Wednesday.<figure class="image"><img style="aspect-ratio:796/231;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_07_24_at_11_50_08_AM_6caa3c3407.png" alt="Retail sentiment trends in the neutral zone for Ionis Pharmaceuticals" width="796" height="231"><figcaption>Retail sentiment trends in the neutral zone for Ionis Pharmaceuticals</figcaption></figure>Photo Courtesy: Samuel Regan-Asante on Unsplash

Wall Street Upgrades Spotify, Lockheed Martin, Ionis Pharmaceuticals: Here’s How Retail Is Reacting

Spotify, Lockheed Martin and Ionia Pharmaceuticals witnessed upgrades by well-known brokerage firms. Here’s a look at how retail investors are reacting to the news

Spotify, Lockheed Martin, Ionis Pharmaceuticals upgrades by Goldman Sachs

Equity

While retail sentiment remains neutral for Spotify and Ionis Pharmaceuticals, investors are optimistic on Lockheed Martin

Ionis Pharmaceuticals' ION582: Promising Angelman Syndrome Drug Faces Clinical and Commercial Uncertainties

Leerink Partners analyst Mani Foroohar has maintained their neutral stance on IONS stock, giving a Hold rating on July 22. Mani Foroohar has given...

Ionis Pharmaceuticals' ION582 Garners Buy Rating Amidst Promising Efficacy and Safety Data

Analyst Jason Gerberry from Bank of America Securities reiterated a Buy rating on Ionis Pharmaceuticals (IONS Research Report) and increased the...

Ionis announces positive detailed results from the HALOS Study of ION582 in people with Angelman syndrome

Ionis announces positive detailed results from the HALOS Study of ION582 in people with Angelman syndrome Ionis announces positive detailed results from the HALOS Study of ION582 in people with...

Ionis to hold second quarter 2024 financial results webcast

Ionis to hold second quarter 2024 financial results webcast Ionis to hold second quarter 2024 financial results webcast PR Newswire CARLSBAD, Calif., July 19, 2024 Webcast scheduled for Thursday...

Ionis completes enrollment in pivotal trial evaluating zilganersen in people living with Alexander disease

Ionis completes enrollment in pivotal trial evaluating zilganersen in people living with Alexander disease Ionis completes enrollment in pivotal trial evaluating zilganersen in people living with...

Alltrna Announces Updates to Its Board of Directors

Alltrna Announces Updates to Its Board of Directors Alltrna Announces Updates to Its Board of Directors PR Newswire CAMBRIDGE, Mass., July 17, 2024 Chris Schade appointed as Board ChairpersonLynne...

Ionis announces webcast to report HALOS study results for ION582 in Angelman syndrome

Ionis announces webcast to report HALOS study results for ION582 in Angelman syndrome Ionis announces webcast to report HALOS study results for ION582 in Angelman syndrome PR Newswire CARLSBAD...

Assessing Ionis Pharmaceuticals: Insights From 6 Financial Analysts

Latest Ratings for IONS
 DateFirmActionFromTo Mar 2022GuggenheimInitiates Coverage OnBuy Mar 2022CitigroupInitiates Coverage OnSell Feb 2022SVB LeerinkMaintainsMarket Perform
 View More Analyst...

Ionis announces olezarsen FCS New Drug Application accepted for Priority Review and enrollment in Phase 3 sHTG program completed

Ionis announces olezarsen FCS New Drug Application accepted for Priority Review and enrollment in Phase 3 sHTG program completed Ionis announces olezarsen FCS New Drug Application accepted for...

Ionis Pharmaceuticals, Inc. engages in the development and commercialization of human therapeutic drugs using antisense technology. It operates through the Ionis Core segment. The Ionis Core segment exploits a novel drug discovery platform to generate a pipeline of drugs. The company was founded by Stanley T. Crooke, David J. Ecker, Christopher K. Mirabelli, and Brett P. Monia on January 10, 1989 and is headquartered in Carlsbad, CA.

Volume	766,354.00
52-Wk High	$54.44
52-Wk Low	$35.95

IONS Ionis Pharmaceuticals Inc

About

Feed

News

Sentiment

Earnings

Fundamentals